title: Seek and destroy: relating cancer drivers to therapies.
abstract: In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.
authors.affiliation: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Martinez-Ledesma
authors.affiliation: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: de Groot
authors.affiliation: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rverhaak@mdanderson.org.
authors.forename: Roel G W
authors.initials: RG
authors.lastname: Verhaak
mesh_terms: D063646:Carcinogenesis / Q000235:genetics*; D003658:Decision Making, Computer-Assisted; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D057285:Precision Medicine / Q000379:methods*